Home » Stocks » EPIX

ESSA Pharma Inc. (EPIX)

Stock Price: $27.08 USD -0.23 (-0.84%)
Updated Mar 3, 2021 3:59 PM EST - Market closed
Market Cap 1.07B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 33.34M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $27.08
Previous Close $27.31
Change ($) -0.23
Change (%) -0.84%
Day's Open 27.44
Day's Range 26.01 - 27.90
Day's Volume 211,084
52-Week Range 3.00 - 32.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 6 days ago

HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing no...

PRNewsWire - 6 days ago

HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing nov...

PRNewsWire - 1 week ago

VANCOUVER, BC and HOUSTON, Feb. 22, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

PRNewsWire - 2 weeks ago

VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

PRNewsWire - 2 weeks ago

VANCOUVER, BC and HOUSTON, Feb. 16, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

Benzinga - 2 weeks ago

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 fo...

Other stocks mentioned: ANAB, PACB
PRNewsWire - 2 weeks ago

VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

PRNewsWire - 2 weeks ago

VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

PRNewsWire - 2 months ago

VANCOUVER and HOUSTON, Dec. 15, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies fo...

PRNewsWire - 3 months ago

HOUSTON and VANCOUVER, BC, Nov. 10, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies...

PRNewsWire - 4 months ago

HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing no...

PRNewsWire - 4 months ago

HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treat...

PRNewsWire - 5 months ago

HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing...

PRNewsWire - 5 months ago

HOUSTON and VANCOUVER, BC, Sept. 17, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the tre...

PRNewsWire - 5 months ago

HOUSTON and VANCOUVER, BC, Sept. 14, 2020 /PRNewswire/ - ESSA Pharma Inc.

Seeking Alpha - 6 months ago

ESSA's EPI-7386 novel approach to treat prostate cancer by targeting the N-terminal domain androgen receptor inhibitor is now in Phase 1 trials. The first patient was dosed on July 15.

PRNewsWire - 6 months ago

VANCOUVER, BC and HOUSTON, Aug. 6, 2020 /PRNewswire/ - ESSA Pharma Inc.

PRNewsWire - 7 months ago

HOUSTON and VANCOUVER, BC, July 31, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing n...

PRNewsWire - 7 months ago

VANCOUVER, BC and HOUSTON, July 28, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing n...

PRNewsWire - 7 months ago

HOUSTON and VANCOUVER, BC, July 15, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treat...

PRNewsWire - 8 months ago

HOUSTON and VANCOUVER, BC, June 22, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the trea...

Seeking Alpha - 1 year ago

ESSA recently presented promising new data on its next-generation EPI-7386 N-terminal domain androgen receptor inhibitor at ESMO for the treatment of prostate cancer.

Zacks Investment Research - 1 year ago

ESSA Pharma (EPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

About EPIX

ESSA Pharma, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Founded
2009
CEO
Dr. David Ross Parkinson
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
EPIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ESSA Pharma stock is "Strong Buy." The 12-month stock price forecast is 0.75, which is a decrease of -97.23% from the latest price.

Price Target
$0.75
(-97.23% downside)
Analyst Consensus: Strong Buy